Clinical Trial Update: Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate and bevacizumab after first-line chemotherapy in stage IIIB or IV non-small cell lung cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: University of Washington | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED